The authors reported a lower blood-transfusion risk in patients who were treated within 24 h; however, more liberal criteria for blood-transfusion administration (Hb < 90 g/L with signs or symptoms of anemia) were chosen compared to our protocol [18]. Here, GSTM1 is linked to anemia.